Frequency and clinical significance of myeloid-associated antigen expression in blast cells w e r e assessed in 372 consecutive children with a c u t e lymphoblastic leukemia (ALL). A comprehensive panel of myeloid monoclonal antibodies representing seven cluster groups showed myeloidassociated antigen expression in 61 cases (16.4%). 18 of which expressed two o r more antigens. The antigens expressed comprised C D l l b (8.9% of t h e total series), CD13 (6.5%). CD33 (3.2%). CD36 (1.9%). CD15 (1.6%). CD14 (1.3%). and C D w l 2 (1.1% We report here the relationship of myeloid-associated antigen expression to clinical features and treatment outcome in a prospective study of children with ALL. Our results suggest that, in the context of contemporary intensive multiagent treatment, expression of myeloid-associated anti- expression and t h e presence of known adverse prognostic features (eg, higher leukocyte count, nonwhite race, older age). Myeloid-associated antigen expression had no effect on remission induction or event-free survival for t h e 267 children w h o had been treated with t h e s a m e combination of chemotherapeutic a g e n t s ( P = 34). Thus, blast cell expression of myeloid-associated antigens in childhood ALL appears to lack prognostic value in t h e context of contemporary intensive chemotherapy. 0 1990 by The American Societyof Hematology.
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gens on lymphoblasts has no apparent prognostic significance in childhood ALL.
MATERIALS AND METHODS
From August 1983 to September 1988, 424 consecutive children with newly diagnosed ALL were admitted to two successive clinical at St Jude Children's Research Hospital (Memphis, TN). Of these patients, 372 (88%) had complete immunophenotyping, including evaluation of myeloid-associated antigen expression on bone marrow blast cells. Informed consent was obtained for all patients, and the investigations were approved by the institution's clinical trials review committee.
Of 372 patients eligible for study of presenting characteristics related to myeloid-associated antigen expression, 105 were treated with a variety of multiagent treatments based on risk stratification. Therefore, analysis of antigen expression in relation to outcome was restricted to the 267 children treated on our most recently completed clinical trial.I6 All of these children received identical induction therapy comprising prednisone, vincristine, daunorubicin, L-asparaginase, teniposide, cytarabine, and high-dose methotrexate. Intensive continuation therapy for 120 weeks consisted of four pairs of drugs: etoposide plus cyclophosphamide, 6-mercaptopurine plus methotrexate, teniposide plus cytarabine, and prednisone plus vincristine, administered on a randomized basis in either a rapidly alternating or sequential schedule.
Bone marrow cells were stained by standard techniques, including periodic acid-Schiff reagent, Sudan black B, myeloperoxidase, naphthol AS-D chloroacetate esterase, and a-naphthyl butyrate esterase. The presence of more than 3% positive blast cells was considered a positive result. Diagnosis of ALL was based on morphologic and cytochemical criteria of the FAB Cooperative Group." Thus, by definition, all cases had fewer than 3% myeloperoxidase-positive blast cells.
Bone marrow cells were separated on a Ficoll-Hypaque gradient, and only samples containing more than 85% blasts were assayed. Cell surface antigens were detected by a standard indirect immunofluorescence using a panel of monoclonal antibodies (MoAbs) representative of cluster groups described by the International Workshops on Human Leukocyte Differentiation Antigens (Table l) .'*~'9 Fluorescence activity was analyzed by microscopy or by an EPICS C Bow cytometer equipped with a 5-W coherent laser (Coulter, Hialeah, FL). Isotypically matched myeloma immunoglobulins at the same protein concentration were used as negative controls in all experiments. Results were considered positive if 225% of the cells expressed a particular antigen. Leukemic cells were also tested for surface (sIg) and cytoplasmic immunoglobulin (cIg) and, in some cases, for heat-stable (37OC) rosette formation with sheep erythrocytes (E-rosette). Immunophenotypic
Patients.
Morphologic and cytochemical studies. HLA-DR+, CD5-, CD7-, cIg-, sIg-, CALLA'), as previously described.20
Immunophenotyping. MYELOID-ASSOCIATED ANTIGEN EXPRESSION IN ALL
In selected cases, to demonstrate simultaneous expression of lymphoid-and myeloid-associated antigens, two-color immunofluorescence measurements were performed on the EPICS C flow cytometer using the fluorescence isothiocyanate (F1TC)-phycoerythrin (PE) dual-immunofluorescence pr~tocol.~ Human lymphocytes dual-labeled with CD4 conjugated to PE and CD8 conjugated to FITC (Simultest, Becton Dickinson, Mountain View, CA) were used to correct for fluorescent spectrum overlap. In all experiments, negative controls included mouse Ig directly conjugated to FITC or PE.
Differences in the distribution of clinical and biologic features among subgroups of patients were assessed using the y coefficient of association2' for categorical variables or the Spearman rank correlation coefficient for continuous variables. Ninety-five percent confidence intervals were calculated for each estimate. The association is significant at the P i .OS level if the confidence interval does not contain zero. With the sample size of this study, there is an 80% likelihood of detecting differences greater than 20% for categorical variables, or greater than .45 standard deviation between the means for continuous variables (p error = .20). 22 Event-free survival was analyzed by the KaplanMeier procedurez3; early death or failure to enter remission was considered an event at zero time. Differences in event-free survival were compared by the Cox-Mantel test. 24 The cutoff date for statistical analysis was July 15, 1989.
Statistical analysis.

RESULTS
Myeloid-associated cell surface antigen expresison was found in 61 of the 372 cases (16.4%) of childhood ALL. Forty-three cases (1 1.6%) expressed one myeloid-associated antigen and 18 (4.8%) two or more antigens ( Table 2 ). The overall frequency of expression for specific antigens, either aloneor in combination, was as follows: CDl lb, 8.9%; CD13, 6.5%; CD33, 3.2%; CD36, 1.9%; CD15, 1.6%; CD14, 1.3%; and CDwl2, 1.1%. The coexpression of lymphoid-and myeloid-associated antigens was confirmed by double-labeling experiments using dual-fluorescence cytometry in all 18 cases expressing two or more myeloid-associated antigens, and in the cases with one myeloid antigen that were tested (n = 10). The wide overlap in the percentages of blasts expressing lymphoid-or myeloid-associated antigens in the remaining patients indicates that some leukemic cells in each child also coexpressed markers for both lineages. Table 3 summarizes the presenting clinical and laboratory features of patients according to expression of myeloidassociated surface antigen (none, 1 antigen, 2 2 antigens). Presenting features did not differ between cases with expression of one versus two or more myeloid-associated antigens. There were no presenting features associated with the expression of myeloid-associated antigen other than smaller liver size and lower serum lactic dehydrogenase. There was also no apparent presenting feature that would characterize cases that had blast cells expressing CDl lb, CD13, or CD33, the three most commonly encountered antigens (data not shown).
All 267 children treated on the recently concluded clinical trial achieved complete remission. At a median follow-up of 2.5 years, event-free survival did not differ significantly between the patients with (n = 44) and without (n = 223) myeloid-associated antigen expression (P = .34, Fig 1) . Analysis of event-free survival based on the three separate categories of myeloid-associated antigen expression (0, 1, or 2 2 antigens) also showed no significant differences in treatment outcome (P = .26).
DISCUSSION
Lymphoblasts from 16.4% of 372 children with otherwise typical ALL expressed myeloid-associated antigens. This frequency, while similar to that of our earlier r e p~r t ,~ substantially exceeds those in two other studies of childhood ALL.4-'2 We attribute this difference to our use of a more comprehensive panel of MoAbs. Weiner et a1: who reported myeloid-associated antigen expression in only 4.5% of childhood ALL cases, used only CD15 and CD13. Ludwig et all2 reported at 4% frequency based on studies with MoAbs representing four cluster groups (CD13, CD15, CD33, and CDw65). In contrast, we used myeloid MoAbs representing Years seven cluster groups. Had our study been limited to the antibodies used by Weiner et a1 or Ludwig et al, the frequency of myeloid-associated antigen expression would have been 6.7% or 8.3%, respectively. Myeloid antigen expression in the Weiner et a1 study4 was more frequent in T-cell and CALLA-non-T, non-B cases. In contrast, we found no relationship between myeloid antigen expression and CALLA positivity, immunophenotype, or FAB subtype of ALL. Myeloid-associated antigen expression appeared to be associated with smaller liver size and lower serum lactic dehydrogenase level at diagnosis; however, these associations were weak, especially in view of the limitations inherent in multiple significance testing. 25 The ability to detect differences is limited in this relatively small study; it is possible that studies of larger series of patients will show correlations between the expression of specific myeloidassociated antigens and these or other presenting features.
A more important issue is the previously reported adverse prognostic significance of myeloid-associated antigen expression in ALL. Weiner et a1: using prednisone and vincristine induction, reported a complete remission rate of only 81% in children with ALL expressing myeloid-associated antigen (compared with 94% of other patients with ALL). In contrast, we found a complete remission rate of 100% for the 267 cases with or without myeloid-associated antigen expression that were treated in our recently concluded clinical trial. The higher remission rate in our series may have resulted from the use of more intensive multiagent chemotherapy. Induction regimens used for our patients included prednisone, vincristine, daunorubicin, L-asparaginase, teniposide, cytarabine, and high-dose methotrexate. Because some Of these agents are a h 0 effective in treating acute myeloid leukemia, remission may have been achieved in some patients with blasts expressing myeloid-associated antigen who would otherwise have failed induction. In this regard, we have described cases of acute myeloid leukemia with blasts expressing lymphoid-associated antigens that failed myeloiddirected remission induction but achieved complete remission after treatment with prednisone, vincristine, and L-aspar a g i n a~e .~, "~'~ In adult patients with ALL, Sobol et all' reported a high frequency (33%) of myeloid-associated antigen expression using antibodies in only two cluster groups (CD13 and CD33). Myeloid-associated antigen expression was associated with FAB L2 morphology, azurophilic granules, unusual morphology (monocytic features and cytoplasmic buds),13 and significantly poorer treatment outcome." Additional studies are needed to confirm the apparently increased frequency of myeloid-associated antigen expression in adult ALL, and to assess whether the poorer outcomes reported for these patients are related to the specific treatment used or reflect more resistant leukemia.
In summary, we demonstrated that the use of a comprehensive panel of MoAbs shows expression of myeloid-associated antigens in a substantial proportion of children with ALL. With the use of intensive combination chemotherapy, treatment results in these cases were equivalent to those in similar cases that lacked myeloid-associated antigen expression. Regardless of the prognostic value of myeloid-associated antigen expression, further studies of such cases may improve our understanding of leukemogenesis.
